Agilent Technologies, Inc. (NYSE:A) Shares Sold by Atria Investments Inc

Atria Investments Inc lessened its position in shares of Agilent Technologies, Inc. (NYSE:A) by 19.4% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 8,201 shares of the medical research company’s stock after selling 1,979 shares during the period. Atria Investments Inc’s holdings in Agilent Technologies were worth $1,218,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Crewe Advisors LLC raised its position in Agilent Technologies by 114.8% during the 2nd quarter. Crewe Advisors LLC now owns 189 shares of the medical research company’s stock worth $25,000 after buying an additional 101 shares during the last quarter. Livelsberger Financial Advisory acquired a new stake in shares of Agilent Technologies during the 3rd quarter worth about $28,000. Ridgewood Investments LLC acquired a new stake in shares of Agilent Technologies during the 2nd quarter worth about $29,000. Fortitude Family Office LLC lifted its holdings in shares of Agilent Technologies by 68.3% during the 3rd quarter. Fortitude Family Office LLC now owns 234 shares of the medical research company’s stock worth $35,000 after acquiring an additional 95 shares during the period. Finally, Ashton Thomas Private Wealth LLC purchased a new position in shares of Agilent Technologies during the 2nd quarter worth about $39,000.

Insider Transactions at Agilent Technologies

In other news, SVP Dominique Grau sold 9,990 shares of the business’s stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $145.00, for a total transaction of $1,448,550.00. Following the sale, the senior vice president now directly owns 40,011 shares in the company, valued at approximately $5,801,595. The trade was a 19.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Padraig Mcdonnell sold 1,958 shares of the business’s stock in a transaction that occurred on Thursday, August 22nd. The shares were sold at an average price of $145.00, for a total value of $283,910.00. Following the sale, the chief executive officer now owns 24,118 shares in the company, valued at approximately $3,497,110. This represents a 7.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 11,995 shares of company stock worth $1,739,510 over the last three months.

Analyst Upgrades and Downgrades

Several research analysts recently commented on A shares. Wells Fargo & Company assumed coverage on shares of Agilent Technologies in a report on Tuesday, August 27th. They issued an “overweight” rating and a $157.00 price target on the stock. TD Cowen lifted their price objective on shares of Agilent Technologies from $153.00 to $160.00 and gave the stock a “buy” rating in a report on Thursday, August 22nd. UBS Group lifted their price objective on shares of Agilent Technologies from $141.00 to $150.00 and gave the stock a “neutral” rating in a report on Thursday, August 22nd. Bank of America raised their target price on Agilent Technologies from $140.00 to $147.00 and gave the company a “neutral” rating in a research note on Thursday, August 22nd. Finally, Evercore ISI raised their target price on Agilent Technologies from $135.00 to $145.00 and gave the company an “in-line” rating in a research note on Tuesday, October 1st. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and nine have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $144.36.

Agilent Technologies Trading Down 2.4 %

NYSE:A opened at $127.07 on Friday. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.78 and a quick ratio of 1.37. Agilent Technologies, Inc. has a fifty-two week low of $112.06 and a fifty-two week high of $155.35. The stock’s 50-day moving average is $138.73 and its two-hundred day moving average is $138.00. The stock has a market cap of $36.51 billion, a PE ratio of 26.36, a price-to-earnings-growth ratio of 5.91 and a beta of 1.07.

Agilent Technologies (NYSE:A) last announced its quarterly earnings results on Wednesday, August 21st. The medical research company reported $1.32 EPS for the quarter, beating the consensus estimate of $1.26 by $0.06. Agilent Technologies had a return on equity of 25.26% and a net margin of 21.75%. The business had revenue of $1.58 billion during the quarter, compared to analysts’ expectations of $1.56 billion. During the same quarter in the previous year, the business posted $1.43 EPS. The firm’s quarterly revenue was down 5.6% compared to the same quarter last year. As a group, equities research analysts forecast that Agilent Technologies, Inc. will post 5.24 earnings per share for the current fiscal year.

Agilent Technologies Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, October 23rd. Investors of record on Tuesday, October 1st were issued a $0.236 dividend. The ex-dividend date was Tuesday, October 1st. This represents a $0.94 annualized dividend and a yield of 0.74%. Agilent Technologies’s dividend payout ratio (DPR) is currently 19.50%.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.